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Background
Constipation is a common condition affecting
all age groups. It is defined as the infrequent and
difficult passage of stool.1
One of the most common constipation myths is
that a person must have a daily bowel movement.
In healthy individuals, bowel movement
frequency varies from three times a day to three
per week. With infrequent bowel movements, a
person may have difficulty in passing a stool and
may experience straining or a feeling of
incomplete bowel evacuation. This may be
accompanied by a feeling of pain.1
Another myth about infrequent bowel
movements is that waste materials in the stool will
be absorbed, poison the body, and shorten one’s
life. This “autointoxication” concept is not
supported with scientific evidence.2
These common myths lead many to perceive
they are constipated when they are not and
contribute to widespread overuse and abuse of
laxatives.

Commentary
Common causes of constipation include poor
diet lacking fiber, inadequate fluid intake, and
poor bowel habits. Constipation can result from
diseases or conditions such as fissures or
hemorrhoids, hypothyroidism, irritable bowel
syndrome, lupus, scleroderma, multiple sclerosis,
Parkinson’s disease, spinal cord injury, tumors,
and cancers.
Loss of body fluids through
vomiting or diarrhea, extended travel, and
prolonged inactivity are also causes. Pregnancy is
a common cause of constipation. Medications
with
anticholinergic
activity,
aluminum
containing antacids, iron supplements, calcium
channel blockers, opioids, and others frequently
cause constipation.
Whenever constipation lasts for longer than
three weeks, presents with severe painful

symptoms, is accompanied by rectal prolapse or
any bleeding, a physician or other healthcare
professional should be consulted.
Frequently, dietary or lifestyle changes will
improve the occasional bout of constipation.
Adequate fluid intake, a well-balanced diet with
ample fruits and vegetables, and regular exercise
will minimize problems.
Those suffering from chronic constipation will
need a prescriptive treatment plan. This plan
usually starts with fiber laxative supplementation,
which is gradually increased until a goal of 20 g
per day is reached. The addition of a saline
laxative, such as milk of magnesia, is the usual
second step in treating chronic constipation.
When these steps fail, the use of stimulant
laxatives is recommended.3
Recommended treatments for patients at the
initiation of opioid therapy include stool softeners
such as docusate in combination with a stimulant
laxative. Bulk-producing fiber agents are not
recommended for use in combating opioidinduced constipation.4
One of the myths about constipation centers
around the chronic use of stimulant laxatives.
Traditional thought on these stimulants has been
that they are for short-term use only. Their longterm use was believed to decrease normal colon
function through detrimental effects on enteric
nerve and smooth muscle. Other myths include
increased risk of cancer, tolerance, and addiction
or abuse due to chronic use of stimulant
laxatives.2
Stimulant laxatives containing aloe, cascara
sagrada, casanthranol, cascara bark, and their fluid
extracts were removed from the market in 2002
because they were not recognized by the FDA as
safe and effective.3 Manufacturers of products
containing these ingredients failed to provide the
FDA with data needed for them to stay on the
market.3
More. . .

Copyright © 2005 by Therapeutic Research Center
Pharmacist’s Letter / Prescriber’s Letter ~ P.O. Box 8190, Stockton, CA 95208 ~ Phone: 209-472-2240 ~ Fax: 209-472-2249
www.pharmacistsletter.com ~ www.prescribersletter.com

(Detail-Document #210309: Page 2 of 3)

The myth that stimulants have detrimental
effects on enteric nerve and smooth muscle is not
supported by clinically documented studies.
Rather, studies were uncontrolled and only
observational in humans and animals. Some
studies involved patients who used laxatives for
longer than ten years at 18 times the
recommended doses.2,5 One controlled trial of
anthraquinone laxative use in constipated women,
using biopsy and electron microscopy with
subsequent ultra morphometry, did not reveal any
degenerative changes in colonic nerve tissue for
either group.6
An association of stimulant laxatives and
increased risk of cancer has not been
demonstrated. In a metaanalysis of 14 prior
studies of cathartic agents, it was found that
constipation and cathartics were associated with a
much lower odds ratio than various dietary
components, such as fat, meat, alcohol, and lowresidue diets.7 Phenolphthalein was banned by the
FDA because of increased cancer risk in animals.
Yet a subsequent large case-controlled study
disproved the association and identified that doses
used in the animal studies excessively exceeded
human doses.2 In 1998 the FDA requested
carcinogenicity data on both bisacodyl and senna.
When bisacodyl animal model study results were
submitted to the FDA, the agency concluded that
the drug was safe and effective when used at the
recommended dose and did not display any tumor
The final over-the-counter
risks for humans.2
(OTC) laxative monograph rule, effective
November 5, 2002, stated that data were
submitted to the FDA regarding senna’s safety
and efficacy as an OTC laxative, and that future
publications would address senna’s role as an
acceptable OTC laxative. It also stated that
stimulant laxative ingredients like cascara or
casanthranol be reformulated to contain senna
instead.8
Tolerance, the need to increase laxative dose to
maintain the desired response, may be uncommon
in most laxative users.2 Though not extensively
studied in humans, a clinical study by Preston and
Lennard-Jones did not show a loss of stimulant
laxative effect except in patients with slow-transit
constipation.2,9 With worsening constipation, the
dose of a laxative may need to be increased but
not because of reduced efficacy.
The myth that stimulant laxatives cause
addiction or abuse results from the belief that their

use contributes to weight-loss. Laxative-induced
diarrhea for the purpose of weight loss is not a
therapeutic goal.
Prevention of constipation is an optimal goal
for everyone.
Eating a well-balanced diet that
includes grains, fresh fruits and vegetables, along
with drinking plenty of fluids, and exercising
regularly will help with prevention. Knowledge
about normal bowel movement frequency
alleviates many fears.
When constipation does occur, fiber laxatives
are a first choice for treatment. Constipation
lasting longer than three weeks or when
accompanied by pain or bleeding should be
discussed with a healthcare professional. When
laxatives are needed for treating a medical
condition or as part of a treatment plan for druginduced constipation, chronic laxative use should
not be fraught with fear because of myths or
misconceptions.

Users of this document are cautioned to use their own
professional judgment and consult any other necessary
or appropriate sources prior to making clinical
judgments based on the content of this document. Our
editors have researched the information with input
from experts, government agencies, and national
organizations. Information and Internet links in this
article were current as of the date of publication.
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